Radiation oncologist in MO | @RadoncTables | Tweets = my own
Joined March 2020
- Tweets 199
- Following 348
- Followers 799
- Likes 287
13 Photos and videos
25 Apr 2025
From one perspective, INSEMA and SOUND are poorly designed and underpowered clinical trials for RNI.
SOUND authors themselves write in the discussion that the trial was not powered to detect differences from adjuvant treatments.
1
5
119
25 Apr 2025
The INSEMA authors write that omission of SLNB was must be weighed against potential benefit of RNI.
If RNI was a requirement in those with 1-3 nodes, and the trial was properly powered, EBCTCG 2023 suggests the results may have been different.
4
115
4 Nov 2022
RTOG 1112
Median OS 15.8 vs. 12.3 mos
Median PFS 9.2 vs. 5.5 mos
TTP also improved
Grade 3 toxicity not different
KEYNOTE-240 (pembro)
Median OS 13.9 vs. 10.6 mos
Median PFS 3.0 vs. 2.8 mos
Grade 3 events 53% vs. 46%
2/3
1
4
4 Nov 2022
STRIDE (tremelimumab durvalumab)
Median OS 16.4 vs. 13.8 mos
3-yr OS 31% vs. 20%
Median PFS not different
Grade 3-4 events similar
Checkmate 459 (nivolumab)
Median OS 16.4 vs. 14.7 mos
2-yr OS 37% vs. 33%
Median PFS 3.7 vs. 3.8 mos
3/3
1
Chris Estes retweeted
25 Oct 2022
Lunch at #ASTRO22 from @towerofamericas
@jryckman3 @radoncreview @_ShankarSiva @ShaneNeibart @EstesRadonc @ASTRO_org
2
21
8 Sep 2022
Fun article from Jerome M Karp on why we're called radiation oncology, and the ins and outs of the grammar involved
But if we change our name to radio-oncology, does that mean we like to listen to FM radios while treating cancer?
DOI:doi.org/10.1016/j.prro.2022.…
3
10 Aug 2022
TROG BIG published!
📌DCIS
➡️ 16 Gy boost 🏆 vs no boost
5-yr LC 97% vs 93%
➡️ Hypofx 🏆 vs conventional
No diff in LC
No differences on subanalysis by any factor, inc hypofx/conv
thelancet.com/journals/lance…
1
26
65
10 Aug 2022
Toxicity
Grade 2 breast pain
14% vs 10%
Grade 2 induration
14% vs 6%
Might lead some to have caution, rx 10 Gy, or use SIB boost, or wait for longer f/u
3
5
10 Aug 2022
Massive trial with 11 countries participating!
Publication in Lancet.
Potentially practice changing for many
6
Chris Estes retweeted
22 Jul 2022
8
15
119
Chris Estes retweeted
15 Jul 2022
Interesting propensity analysis from the STRASS authors comparing STRASS patients with a cohort of those not enrolled in the study, from same centers (“STREXIT” 🙅♂️)
In the cohort, pre-op RT improved ARFS in well-differentiated liposarcoma and G1-2 dediff LPS ✅
1
2
2
22 Jul 2022
⭐️RT for borderline pancreas on RadOnc Tables
Two trials: CONKO-007 and Alliance
ALLIANCE
📌 RT arm terminated early due to low R0 at n=30 patients.
📌 All pCRs were in RT arm even after full enrollment of chemo alone arm. Potentially underpowered
jamanetwork.com/journals/jam…
1
6
8
22 Jul 2022
1
1
22 Jul 2022
Summary:
📌 In both trials, the only pCRs were in the RT arms
📌 RT may improve LC, R0, and pCR rates
📌 Potential role for RT in borderline pancreas
3